Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of regorafenib in patients with metastatic melanoma harboring c-Kit
mutations and/or amplifications of c-Kit gene copy number. The primary end point is disease
control rate (DCR), and the secondary end points are safety, response rate (RR), progression
free survival (PFS), and overall survival (OS).